Suggestions for reform were small beer, including more collaboration among government, industry and academia; more scholarships to train "translational" researchers to bridge the gap between basic science and medicine; more incentives for innovative drug research; and patents for breakthrough drugs extended from the current 20 years to 25-30 years, and those for "me too" drugs shortened to 10 years.
Too bad that Time failed to address just abolishing the drug patent system or Stiglitz' idea to have government fund drug development costs.
